AI and big data predict which research will influence future medical treatments

An artificial intelligence/machine learning model to predict which scientific advances are likely to eventually translate to the clinic has been developed by Ian Hutchins and colleagues in the Office of Portfolio Analysis (OPA), a team led by George Santangelo at the National Institutes of Health (NIH). This work, described in a Meta-Research article published October 10 in the open-access journal PLOS Biology, aims to decrease the sometimes decades-long interval between scientific discovery and clinical application; the method determines the likelihood that a research article will be cited by a future clinical trial or guideline, an early indicator of translational progress.

Hutchins and colleagues have quantified these predictions, which are highly accurate with as little as two years of post-publication data, as a novel metric called "Approximate Potential to Translate" (APT). APT values can be used by researchers and decision-makers to focus attention on areas of science that have strong signatures of translational potential. Although numbers alone should never be a substitute for evaluation by human experts, the APT metric has the potential to accelerate biomedical progress as one component of data-driven decision-making.

The model that computes APT values makes predictions based upon the content of research articles and the articles that cite them. A long-standing barrier to research and development of metrics like APT is that such citation data has remained hidden behind proprietary, restrictive, and often costly licensing agreements. To disrupt this impediment to the scientific community, to increase transparency, and to facilitate reproducibility, OPA has aggregated citation data from publicly available resources to create an open citation collection (NIH-OCC), the details of which appear in a Community Page article in the same issue of PLOS Biology. The NIH-OCC comprises over 420 million citation links at present and will be updated monthly as citations continue to accumulate. For publications since 2010, the NIH-OCC is already more comprehensive than leading proprietary sources of citation data.

Citation data from the NIH-OCC are used to calculate both APT values and Relative Citation Ratios (RCRs). The latter, a measure of scientific influence at the article level, normalized for the field of study and time since publication, was developed previously by Santangelo's team at NIH, and has already been widely adopted in both the scientific and evaluator communities. Upon publication of these two articles, APT values and the NIH-OCC will be freely and publicly available as new components of the iCite webtool that will continue as the primary source of RCR data (https://icite.od.nih.gov/). The OPA team encourages the use of iCite to improve research assessment and decision-making that can contribute to optimizing the scientific enterprise.

Hutchins BI, Davis MT, Meseroll RA, Santangelo GM.
Predicting translational progress in biomedical research.
PLOS Biology 17(10). doi: 10.1371/journal.pbio.3000416.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...